Evidence map›Paper›PMID 39546438›Full record

ArticleRevista medica del Instituto Mexicano del Seguro Social2024

[Primary central nervous system lymphoma in immunocompetent patient: A case report].

Diego Alejandro Garzón-Recalde, Elizabeth Rentería-Castillo, Carlos César Esparza-Ibarra

Abstract readCase ReportsEnglish Abstract
In one paragraph

Article in Revista medica del Instituto Mexicano del Seguro Social, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Diego Alejandro Garzón-RecaldeInstituto Mexicano del Seguro Social. Centro Médico Nacional Siglo XXI, Hospital de Especialidades "Dr. Bernardo Sepúlveda Gutiérrez", Servicio de Medicina Interna. Ciudad de México, México.ORCID 0000-0003-2407-9940
Elizabeth Rentería-CastilloInstituto Mexicano del Seguro Social. Hospital General de Zona 2-A "Francisco del Paso y Troncoso", Servicio de Hematología. Ciudad de México, México.ORCID 0000-0001-5271-1179b
Carlos César Esparza-IbarraInstituto Mexicano del Seguro Social. Centro Médico Nacional Siglo XXI, Hospital de Especialidades "Dr. Bernardo Sepúlveda Gutiérrez", Servicio de Medicina Interna. Ciudad de México, México.ORCID 0009-0009-9140-6885c

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Primary central nervous system lymphoma (PCNSL) is an extranodal lymphoid neoplasm that affects the brain, spinal cord, leptomeninges or the vitreous-retina space, without systemic involvement. It represents 3% of CNS tumors predominantly in the context of immunosuppression (HIV infection, post-transplant). The clinical presentation and radiological findings are highly variable, representing a diagnostic challenge especially in immunocompetent patients. Its prognosis is unfavorable despite the high response to initial treatment. Clinical case: 69-year-old man, hospitalized for upper motor neuron syndrome and intracranial hypertension. No abnormal laboratory studies were found and a contrast-enhanced tomography of the head revealed multiple contrast-enhancing lesions with vasogenic edema. Extension studies in search of a primary tumor were negative. MRI demonstrated lesions with characteristics consistent with lymphoma. A PET/CT with 18-fluorodeoxyglucose was performed, which ruled out systemic involvement, and a brain biopsy confirmed PCNSL with histopathologic features of a diffuse large B cell lymphoma. The patient was sent to the hemato-oncology department at a third level hospital for chemotherapy, he completed two cycles of high-dose methotrexate plus rituximab without response and fatal outcome. Conclusions: PCNSL is an aggressive, low-incidence, extranodal lymphoma, which should be considered in immunocompetent patients over 60 years old with multiple brain lesions, in order to initiate treatment in a timely manner.

Indexed as

ImmunocompetenceLymphoma, Large B-Cell, DiffuseAgedCentral Nervous System NeoplasmsFatal OutcomeHumansMaleCentral Nervous System NeoplasmsDiffusion Magnetic Resonance ImagingImmunocompetenceImmunohistochemistryLymphoma, Large B-Cell, DiffuseLymphoma, Non Hodgkin

Identifiers

PMID39546438
PMCPMC12360826

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.